|Home | About Bipolar Disorder | About David Oliver | Bipolar Articles/Stories | Bipolar Success Stories | Blogs and Podcast | Catalog | Contact | Current Bipolar News David Oliver In the News | Donate | Events | FAQ's | FREE Resources | Health Directory | Other Illnesses | Recommended Sites | Site Map | Speaking | Testimonials|
November 7, 2005
Note: One or more of the following articles may require a subscription to view the entire article. We cannot post articles that require a subscription. We are sorry for the inconvenience.
SEROQUEL named product of the year
Seroquel Clinical Study for Bipolar Depression - Week 2
How a Cholinergic Boost Affects the Young and Old
Family Awarded In Prisoner Death Settlement
Aetna To Increase Payments to Physicians Participating in Depression Management Program, USA Click here for more.
Forum to address controversies over antidepressants Click here for more.
PND, When A Mother Is Depressed - Cohospitalise with children or without? Click here for more.
Talk therapy more effective long-term treatment for SAD than light therapy, study finds Click here for more.
Largest survey on depression suggests higher prevalence in U.S., reports Mailman school Click here for more.
Advice for Reducing Holiday Stress Click here for more.
2006 Medicare Outpatient Reimbursement Rates for Cyberonics' VNS Therapy(TM) Posted on CMS Website.
PR Newswire; 11/3/2005
Hospital Reimbursement for VNS Implants Increases for the Third Consecutive Year
HOUSTON, Nov. 3 /PRNewswire-FirstCall/ -- Cyberonics, Inc. today announced that 2006 Medicare outpatient reimbursement rates for Cyberonics' VNS Therapy System have been posted on the CMS website (http://www.cms.hhs.gov/providers/hopps/2006fc/ ). Beginning January 2006, average Medicare reimbursement to hospitals for outpatient implantation of the VNS Therapy System increases 8.6% to $26,649 for the implantation and intra- operative programming of the VNS Therapy Systems as follows: $11,603 under APC 0039 for implantation of neurostimulator, $14,928 under APC 0225 for implantation of neurostimulator electrodes, and $118 under APC 0692 for the intra-operative electrode test.
"Cyberonics is very pleased with Medicare's decision to once again increase hospital reimbursement for implantation of the VNS Therapy System," commented Robert P. ("Skip") Cummins, Cyberonics' Chairman and Chief Executive Officer. "Over the past three years, Medicare hospital reimbursement for implantation of the VNS Therapy System has increased 37% from $19,500 to $26,649. This steady increase confirms that Cyberonics continues to develop therapies that satisfy the needs of not only patients with chronic, treatment- resistant illnesses and their physicians, but also payers."
ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc. was founded in 1987 to design, develop and market medical devices for the long-term treatment of epilepsy, depression and other chronic treatment-resistant disorders using a unique therapy, vagus nerve stimulation (VNS). Stimulation is delivered by the VNS Therapy System(TM), an implantable generator similar to a cardiac pacemaker. The VNS Therapy System delivers preprogrammed intermittent mild electrical pulses to the vagus nerve in the patient's neck 24 hours a day. The Company's initial market was epilepsy, a disorder characterized by recurrent seizures. Epilepsy is the second most prevalent neurological disorder. The Cyberonics VNS Therapy System was approved by the FDA on July 16, 1997 for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications. The VNS Therapy System is also approved for sale as a treatment for epilepsy in all the European Economic Area, Canada, Australia and other markets. To date, more than 32,000 epilepsy patients in 24 countries have accumulated over 100,000 patient years of experience using VNS Therapy.
The VNS Therapy System was approved by the FDA on July 15, 2005 "as an adjunctive long-term treatment for chronic or recurrent depression for patients 18 years of age and older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments." As part of FDA's approval order, Cyberonics is required to conduct a 450-patient post-market dosing study and a 1,000-patient, five-year patient outcome registry. For more information on VNS Therapy for treatment-resistant depression, including the contraindications, warnings and precautions, see the Physician's and Patient's Manuals and other information at http://www.cyberonics.com/ or http://www.vnstherapy.com/ or call 1-877-NOW 4 VNS.
The VNS Therapy System has been approved for sale in the European Economic Area and in Canada as a treatment for depression in patients with treatment- resistant or treatment-intolerant major depressive episodes, including unipolar depression and bipolar disorder (manic depression) since 2001.
VNS Therapy is at various levels of investigational clinical study as a potential treatment for anxiety disorders, Alzheimer's disease, chronic headache/migraine and bulimia. The Company is headquartered in Houston, Texas and has an office in Brussels, Belgium. For additional information please visit us at http://www.cyberonics.com/ .
CONTACT: Investor Relations of Cyberonics, Inc., +1-281-228-7262, or fax, +1-281-218-9332, or InvestorRelations@cyberonics.com ; or Helen Shik, Vice President of Schwartz Communications, +1-781-684-0770 ext. 6587, or fax, +1-781-684-6500, or firstname.lastname@example.org , for Cyberonics, Inc.
Web site: http://www.cyberonics.com/ http://www.vnstherapy.com/ http://www.cms.hhs.gov/providers/hopps/2006fc
COPYRIGHT 2005 PR Newswire Association LLC
This Week's Bipolar News
The Impact Of Insulin Resistance On The Course Of Bipolar Disorder
Mood Disorder, Obesity Associated With Poorer Physical, Mental Outcomes
Click here for all Bipolar News.
The Warning Signs Of An Impending Bipolar Disorder Manic Episode
Bipolar disorder - as the name implies - involves two distinct set of symptoms. One set throws the individual down into the depths of a massive depression. The other places the individual who suffers with bipolar disorder at the top of a peak manic episode.
Most everyone can eventually recognize the warning signs of an impending depressive episode related to bipolar disorder. More likely than not, individuals with bipolar disorder try very hard to avoid it.
However, for many individuals with bipolar disorder, it's more difficult to recognize the signs of an impending manic episode. After all, a manic episode of bipolar disorder can be mistaken in some cases - especially in the very early formation -- for the lifting of the corresponding mood swing of the depression.
Home | About
Bipolar Disorder |
About David Oliver | Bipolar
Articles/Stories | Bipolar
Success Stories | Blogs
and Podcast | Catalog |
| Current Bipolar
David Oliver In the News | Donate | Events | FAQ's | FREE Resources | Health Directory | Other Illnesses | Recommended Sites | Site Map | Speaking | Testimonials
| The information contained
on this web page is not meant to provide medical advice.
Specific medical advice should be obtained from a qualified and licensed health-care practitioner.
There is no warranty that the information is free from all errors and omissions or that it meets any particular standard.
Copyright 2004- 2019 , BipolarCentral.com